<DOC>
	<DOCNO>NCT02528643</DOCNO>
	<brief_summary>The purpose study evaluate efficacy enzalutamide subject advance hepatocellular carcinoma ( HCC ) measure overall survival ( OS ) . This study also evaluate safety enzalutamide ; pharmacokinetics enzalutamide active metabolite N-desmethyl Progression Free Survival ( PFS ) enzalutamide compare placebo subject advance HCC .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Enzalutamide Subjects With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Subject ≥ 18 year age consider adult accord local regulation time sign informed consent . Subject documented diagnosis advance HCC etiology . Subject BCLC stage B C. Subject 's lesion amenable local therapy may beneficial , transarterial chemoembolization ( TACE ) , radiofrequency ablation , radiotherapy , etc. , subject candidate curative treatment resection liver transplant . Subject hepatic function status Child Pugh Class A Screening . Subject receive prior systemic treatment HCC sorafenib antiVEGF therapy confirm disease progression discontinue treatment due drugrelated toxicity . Subject may receive 1 line systemic therapy sorafenib/antiVEGF treatment . Subject adequately recover toxicity due prior HCC therapy ≤ grade 1 . Subject ECOG performance status ≤ 1 Screening Day 1 . Subject available formalinfixed , paraffinembedded tumor specimen adequate viable tumor cell tissue block unstained serial slide accompany associated pathology report prior enrollment . Archival fresh biopsy tissue require . Subject estimate life expectancy least 3 month Day 1 , opinion investigator . Female subject either : Not childbearing potential : postmenopausal ( define spontaneous menses least 12 consecutive month prior Screening folliclestimulating hormone [ FSH ] &gt; 40 IU/L woman &lt; 55 year age Screening ) , document surgically sterile status posthysterectomy ( least 1 month prior Screening ) . Or , childbearing potential : must negative urine pregnancy test Screening Day 1 first dose study drug administer , must use 2 acceptable method birth control* sexually active Screening 3 month last dose study drug . Sexually active male subject female partner childbearing potential must use 2 acceptable method birth control Screening 3 month last dose study drug . * Two acceptable method birth control follow : Condom ( barrier method contraception ) ; AND One following require : Placement intrauterine device ( IUD ) intrauterine system ( IUS ) female subject female partner male subject ; Additional barrier method : contraceptive sponge occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository female subject female partner male subject . For male subject male partner female subject , vasectomy procedure result infertility ( e.g. , bilateral orchiectomy ) perform least 6 month Screening . Tubal ligation female partner male subject perform least 6 month Screening . Established ongoing use oral , injected , implanted hormonal contraceptive female partner male subject . Female subject must breastfeed Screening study period 3 month final study drug administration . Subject must agree donate sperm ova first dose study drug 3 month last dose study drug . Throughout study , male subject must use condom sex pregnant woman . Subject must able swallow study drug comply study requirement . Subject agree participate another interventional study treatment . Subject severe concurrent disease , infection comorbidity , judgment investigator , would make subject inappropriate enrollment . Subject fibrolamellar variant HCC . Subject status ChildPugh Class B C Screening . Subject history organ allograft include liver transplant . Subject uncontrolled symptomatic ascites . Subject know suspected brain metastasis active leptomeningeal disease . Subject history nonHCC malignancy follow exception : The subject previous history noninvasive carcinoma eligible opinion investigator he/she successful curative treatment time prior Screening require therapy malignancy . For malignancy , subject eligible he/she undergone potentially curative therapy consider disease free least 3 year prior Screening . Subject inadequate marrow , hepatic , and/or renal function Screening Visit define : Absolute neutrophil count &lt; 1.5 x109/L ( &lt; 1500 cells/mm3 ) Platelet count &lt; 50 x109/L ( &lt; 50,000 cells/mm3 ) Hemoglobin &lt; 8.5 g/dL ( &lt; 5.3 mmol/L ) International normalize ratio &gt; 1.7 Albumin &lt; 2.8 g/dL ( &lt; 28 g/L ) Total bilirubin ( TBL ) &gt; 2 x ULN AST ALT &gt; 5 x ULN Creatinine &gt; 1.5 x ULN Note : Transfusions/infusions meet eligibility criterion allow opinion Principal Investigator , beneficial , patient may rescreened receive one procedure . Subject history seizure condition may predispose seizure ( e.g. , prior cortical stroke , significant brain trauma , encephalopathy within 3 month Day 1 ) . Subject history bleed esophageal varix within 3 month Day 1 visit . Subject history loss consciousness transient ischemic attack within 12 month Day 1 visit . Subject clinically significant cardiovascular disease include : Myocardial infarction within 6 month Day 1 visit . Uncontrolled angina within 6 month Day 1 visit . Congestive heart failure New York Heart Association ( NYHA ) Class III IV history congestive heart failure NYHA Class III IV past , unless Screening echocardiogram multigated acquisition scan perform within 3 month Day 1 visit reveals leave ventricular ejection fraction ≥ 45 % . History clinically significant ventricular arrhythmia ( e.g. , ventricular tachycardia , ventricular fibrillation , Torsade de Pointes ) . History Mobitz II second degree third degree heart block without permanent pacemaker place . Hypotension indicate systolic blood pressure &lt; 86 mmHg 2 consecutive measurement Screening visit . Bradycardia ( presence know cardiovascular disease ) indicate heart rate &lt; 50 beat per minute Screening electrocardiogram ( ECG ) recording . Uncontrolled hypertension indicate systolic blood pressure &gt; 170 mmHg diastolic blood pressure &gt; 105 mmHg 2 consecutive measurement Screening visit . Subject gastrointestinal disorder affect absorption . Subject previous local therapy ( e.g. , surgery , radiation therapy , hepatic arterial therapy , chemoembolization , radiofrequency ablation , percutaneous ethanol injection cryoablation ) within 14 day prior Day 1 , recover toxicity prior local therapy may require major surgical procedure course study . Subject receive chemotherapy , immunotherapy systemic anticancer therapy ( include sorafenib ) investigational drug within 14 day prior Day 1 visit . Subject receive agent either block androgen synthesis target AR ( e.g. , abiraterone acetate , bicalutamide , enzalutamide , ARN509 investigational AR signal inhibitor ) . The exception spironolactone allow Medical Monitor consultation . Subject use follow within 28 day Day 1 visit : 5α reductase inhibitor Systemic androgens estrogen ( vaginal estrogen cream allow ) Herbal therapy , antitumor effect . Subject known history positive test Human Immunodeficiency Virus . Subject show hypersensitivity reaction active pharmaceutical ingredient enzalutamide capsule component , include caprylocaproyl polyoxylglycerides ( Labrasol ) , butylate hydroxyanisole butylate hydroxytoluene . Subject addictive/substance abuse problem . Subject condition reason , opinion investigator , interfere ability subject participate trial , place subject undue risk complicates interpretation safety data .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MDV3100</keyword>
	<keyword>advanced hepatocellular carcinoma</keyword>
	<keyword>enzalutamide</keyword>
	<keyword>Xtandi</keyword>
	<keyword>ASP9785</keyword>
</DOC>